ClinicalTrials.gg
RecruitingNCT07626060LLM-HEARTUpdated Jun 23, 2026

Diagnostic Accuracy of GPT-4o and Claude for HEART Score Calculation in Chest Pain

An observational study in Emergency Medicine, Artificial Intelligence (AI) and Artificial Intelligence (AI) in Diagnosis, sponsored by Marmara University Pendik Training and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.

Primary conditionnone(registry's first term: Emergencies)No conditionIs this wrong?Emergencies describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Marmara University Pendik Training and Research Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
690
Ages
18 Years and older
Sex
All
01

Study summary

This prospective observational diagnostic accuracy study evaluates whether large language models (LLMs) - GPT-4o (OpenAI, gpt-4o-2024-11-20) and Claude (Anthropic, claude-sonnet-4-6) - can accurately calculate HEART scores from unstructured Turkish clinical notes and predict 30-day major adverse cardiac events (MACE) in emergency department patients presenting with non-traumatic chest pain.

The study will enroll 600 consecutive adult patients. For each patient, the same anonymized data (free-text anamnesis, ECG report text, troponin value, and age) will be independently processed by both LLMs via separate API calls with deterministic settings (temperature=0, JSON format). A three-expert consensus HEART score - derived through blinded independent scoring by three emergency medicine physicians with majority-vote adjudication - serves as the reference standard for agreement analysis. Actual 30-day MACE (all-cause death, AMI Type 1/2/4b, unplanned revascularization) determined via national health database and telephone follow-up serves as the outcome for diagnostic accuracy analysis.

A secondary documentation-quality sub-study will quantify how spontaneously Turkish emergency anamnesis notes capture HEART score parameters.

Read the detailed description

AI SYSTEM SPECIFICATIONS AND PROMPT PROTOCOL Two distinct large language models (LLMs) will be evaluated as index tests: OpenAI GPT-4o (model string: gpt-4o-2024-11-20) and Anthropic Claude (model string: claude-sonnet-4-6). To ensure reproducibility and eliminate stochastic variation, both models will be accessed via standardized API calls using deterministic parameters (temperature = 0, max_tokens = 500, and strict JSON response format). The exact system prompt layout will be locked prior to initialization, and its integrity will be verified using a SHA-256 cryptographic hash. The models will evaluate each patient record independently in zero-shot isolation, with no cross-contamination or conversational history retention between runs.

REFERENCE STANDARD CONSENSUS PROTOCOL The reference standard consists of a structured consensus HEART score established by three independent emergency medicine physicians (each possessing >=3 years of clinical experience and specific training on HEART score criteria). The physicians will review the anonymized clinical charts while remaining strictly blinded to the LLM outputs and the final 30-day MACE outcomes. For each of the 5 HEART components (scored 0, 1, or 2), a majority vote (2/3 agreement) will determine the final component score. In the event of complete disagreement across all three reviewers on a specific component, a fourth independent adjudicator will resolve the tie.

INDETERMINATE RESULTS MANAGEMENT

In strict compliance with STARD-AI 2025 guidelines, cases with missing or uninterpretable parameters within the free-text clinical notes will be classified into predefined indeterminate tiers:

  1. Complete Cases: 0 indeterminate components (eligible for primary diagnostic accuracy analysis).
  2. Partial Indeterminate: Exactly 1 missing component preventing definitive automatic calculation.
  3. Full Indeterminate: >=2 missing components. The proportion of indeterminate classifications will be quantified for both LLMs and evaluated alongside the routine documentation quality of the charts.

STATISTICAL ANALYSIS AND AGREEMENT WEIGHTING Statistical power and sample size calculation are based on the Hanley-McNeil methodology for the Area Under the ROC Curve (AUC). To achieve an expected AUC of 0.85 with a non-inferiority margin of 0.05, a power of 80%, and a two-sided alpha of 0.05, the primary complete-case analysis requires 600 evaluable patients. Accounting for an anticipated 15% indeterminate rate, a total enrollment target of 690 patients is set. Inter-rater agreement between each LLM and the expert consensus will be computed using quadratic weighted Cohen's Kappa for the ordinal total HEART score (0-10) and linear weighted Kappa for individual components (0-2). Diagnostic performance metrics (sensitivity, specificity, PPV, NPV) will be calculated at prespecified binary (>=4) and trimodal thresholds with 95% Wilson confidence intervals. Pairwise comparison of AUC values between GPT-4o and Claude will be executed using the DeLong test.

DATA ANONYMIZATION AND PRIVACY To ensure full compliance with local personal data protection legislation (KVKK), all free-text emergency department notes will undergo strict de-identification. Patient names, institutional ID numbers, precise dates, and specific demographic identifiers will be stripped entirely before formatting the data payload for API transmission.

PATIENT AND PUBLIC INVOLVEMENT BEYANI Patient and public involvement was not applicable to this study as it involves the analysis of routinely collected clinical data.

02

Conditions studied

  • Emergency Medicine
  • Artificial Intelligence (AI)
  • Artificial Intelligence (AI) in Diagnosis
  • Chest Pain Rule Out Myocardial Infarction

Browse trials for

Keywords

  • Large Language Model
  • GPT-4o
  • Claude Sonnet
  • Emergency Department
  • Diagnostic Accuracy
  • Medical Informatics
  • Physician vs AI
  • HEART score
03

In context

Lead sponsor

Marmara University Pendik Training and Research Hospital is the lead sponsor of 34 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of consecutive adult patients presenting with a chief complaint of non-traumatic chest pain to the emergency department of Marmara University Pendik Training and Research Hospital, a tertiary care academic medical center in Istanbul, Turkey. This target population comprises real-world emergency medicine admissions that require acute coronary syndrome risk stratification and evaluation with the HEART score. It excludes individuals presenting with traumatic pain etiologies or acute ST-elevation myocardial infarction (STEMI) requiring immediate, time-critical reperfusion pathways.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >=18 years
  • Chief complaint of non-traumatic chest pain at the emergency department
  • Written obtained from the patient or legally authorized representative
  • Availability for 30-day follow-up (reachable by telephone and/or actively registered in the e-Nabiz national health database)

Exclusion criteria

EXCLUSION CRITERIA:

  • Traumatic chest pain etiology
  • ST-elevation myocardial infarction (STEMI) at presentation requiring immediate reperfusion protocol
  • Refusal or subsequent withdrawal of
  • Inability to complete the mandatory 30-day follow-up period

WITHDRAWAL CRITERIA:

  • Patient or representative requests data withdrawal after initial consent
  • Administrative identification of retrospective data entry after enrollment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
690 participants (estimated)
Patient registry
No

Interventions

  • OtherGPT-4o HEART Score Calculator

    OpenAI GPT-4o (model: gpt-4o-2024-11-20, temperature=0, max\_tokens=500, response\_format=JSON). Each patient's anonymized anamnesis text, ECG report text, troponin value, and age are submitted via a separate API call with no conversation history. Output: HEART score components (0-2 each), total score (0-10), risk group, and indeterminate status.

    Also known as: GPT-4o İndeks Testi

  • OtherClaude HEART Score Calculator

    Anthropic Claude (model: claude-sonnet-4-6, temperature=0, max\_tokens=500, response\_format=JSON). Identical system prompt and input format as GPT-4o. Processed independently with no cross-contamination between models. Output: same JSON schema as GPT-4o.

    Also known as: Claude İndeks Testi

  • OtherThree-Expert Consensus HEART Score

    Three emergency medicine physicians (\>=3 years experience, HEART-score trained) independently score each anonymized record. Majority vote (2/3) determines component scores; a 4th adjudicator resolves ties. Experts are blinded to LLM scores, each other's scores, and MACE outcomes.

    Also known as: Referans Standart

06

What researchers measure

Primary outcomes

  1. Area Under the ROC Curve (AUC) of GPT-4o and Claude HEART Score for 30-Day MACE Prediction

    AUC calculated separately for GPT-4o and Claude using the Hanley-McNeil method. MACE is defined as a composite of all-cause death, acute myocardial infarction (Type 1/2/4b), and unplanned revascularization within 30 days. HEART score range is 0-10; a higher score indicates a higher risk of MACE. Analysis will be performed on complete cases only (0 indeterminate components).

    Time frame: 30 days after index emergency department visit

Secondary outcomes

  1. Sensitivity and Specificity of GPT-4o and Claude HEART Score at Prespecified Thresholds

    Diagnostic sensitivity and specificity calculated at two threshold types: (a) total score \>=4 (binary high-risk cutoff) and (b) trimodal cutoffs (0-3 low risk, 4-6 intermediate risk, 7-10 high risk). Metrics will be reported with 95% Wilson confidence intervals separately for each LLM.

    Time frame: 30 days after index emergency department visit

  2. Component-Level and Total-Score Agreement (Cohen's Kappa) Between LLMs and Expert Consensus

    Inter-rater agreement will be computed using quadratic weighted Cohen's Kappa for the ordinal total HEART score (range 0-10) and linear weighted Kappa for the individual components (range 0-2). Calculated separately for GPT-4o vs. expert consensus and Claude vs. expert consensus. Values will be interpreted using the Landis \& Koch scale (\<0.20 poor, 0.21-0.40 fair, 0.41-0.60 moderate, 0.61-0.80 good, \>0.80 excellent).

    Time frame: Baseline (At index emergency department visit)

  3. Comparative AUC Difference Between GPT-4o and Claude (DeLong Test)

    Statistical comparison of paired ROC curves between GPT-4o and Claude using the DeLong et al. (1988) method. The formal hypothesis is non-inferiority with an expected delta AUC \<= 0.05. The correlation coefficient between the paired LLM measurements is estimated as rho \>= 0.70.

    Time frame: 30 days after index emergency department visit

  4. Proportion of Indeterminate Results for GPT-4o and Claude

    The proportion of cases classified into predefined missing data tiers: Complete (0 indeterminate components), Partial indeterminate (exactly 1 missing component preventing definitive score calculation), and Full indeterminate (\>=2 missing components). Reported separately for each LLM and statistically compared between the two models.

    Time frame: Baseline (At index emergency department visit)

  5. HEART Parameter Documentation Rate in Routine Turkish Anamnesis Notes

    For each of the 5 individual HEART components, the proportion of emergency department free-text anamnesis notes that spontaneously contain sufficient objective clinical information for scoring. Rates will be categorized as: Present and scorable, Partiall

    Time frame: Baseline (At index emergency department visit)

  6. Subgroup AUC by Age Group and Sex (Algorithmic Bias Assessment)

    AUC values for 30-day MACE prediction were calculated separately across demographic strata: age groups (\<45, 45-64, \>=65 years) and biological sex (male vs. female). This analysis serves as the formal algorithmic bias assessment required by the STARD-AI 2025 guidelines.

    Time frame: 30 days after the index emergency department visit

07

Study locations

1 of 1 sites recruiting
  • Marmara University Pendik Training and Research Hospital
    Istanbul, Istanbul 34870, Turkey (Türkiye)
    Recruiting
    • Emir ünal · Contactemirunal@gmail.com · 05327766010
    • Emre Kudu · Sub investigator
    • Erhan Altunbas · Sub investigator
    • Sinan Karacabey · Sub investigator
08

References and documents

Publications

  • Mahler SA, Riley RF, Hiestand BC, Russell GB, Hoekstra JW, Lefebvre CW, Nicks BA, Cline DM, Askew KL, Elliott SB, Herrington DM, Burke GL, Miller CD. The HEART Pathway randomized trial: identifying emergency department patients with acute chest pain for early discharge. Circ Cardiovasc Qual Outcomes. 2015 Mar;8(2):195-203. doi: 10.1161/CIRCOUTCOMES.114.001384. Epub 2015 Mar 3. PubMed 25737484 ↗
  • Singhal K, Azizi S, Tu T, Mahdavi SS, Wei J, Chung HW, Scales N, Tanwani A, Cole-Lewis H, Pfohl S, Payne P, Seneviratne M, Gamble P, Kelly C, Babiker A, Scharli N, Chowdhery A, Mansfield P, Demner-Fushman D, Aguera Y Arcas B, Webster D, Corrado GS, Matias Y, Chou K, Gottweis J, Tomasev N, Liu Y, Rajkomar A, Barral J, Semturs C, Karthikesalingam A, Natarajan V. Large language models encode clinical knowledge. Nature. 2023 Aug;620(7972):172-180. doi: 10.1038/s41586-023-06291-2. Epub 2023 Jul 12. PubMed 37438534 ↗
  • Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, Ghassemi M, Liu X, Reitsma JB, van Smeden M, Boulesteix AL, Camaradou JC, Celi LA, Denaxas S, Denniston AK, Glocker B, Golub RM, Harvey H, Heinze G, Hoffman MM, Kengne AP, Lam E, Lee N, Loder EW, Maier-Hein L, Mateen BA, McCradden MD, Oakden-Rayner L, Ordish J, Parnell R, Rose S, Singh K, Wynants L, Logullo P. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024 Apr 16;385:e078378. doi: 10.1136/bmj-2023-078378. PubMed 38626948 ↗
  • Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG, Moher D, Rennie D, de Vet HC, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF; STARD Group. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015 Oct 28;351:h5527. doi: 10.1136/bmj.h5527. PubMed 26511519 ↗
  • Backus BE, Six AJ, Kelder JC, Bosschaert MA, Mast EG, Mosterd A, Veldkamp RF, Wardeh AJ, Tio R, Braam R, Monnink SH, van Tooren R, Mast TP, van den Akker F, Cramer MJ, Poldervaart JM, Hoes AW, Doevendans PA. A prospective validation of the HEART score for chest pain patients at the emergency department. Int J Cardiol. 2013 Oct 3;168(3):2153-8. doi: 10.1016/j.ijcard.2013.01.255. Epub 2013 Mar 7. PubMed 23465250 ↗
  • Albrecht M. C4-bound imidazolylidenes: from curiosities to high-impact carbene ligands. Chem Commun (Camb). 2008 Aug 21;(31):3601-10. doi: 10.1039/b806924g. Epub 2008 Jul 8. PubMed 18665276 ↗

Individual participant data

Plan to share: Yes — Anonymized individual participant data (including de-identified baseline demographics, clinical presentation characteristics, index test outputs from GPT-4o and Claude, and the reference standard expert consensus HEART scores) will be made publicly available to support academic transparency and replication. Additionally, the complete deterministic system prompt texts (verified with SHA-256 cryptographic hashes) and the complete statistical analysis code will be included as supplementary material.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: The anonymized dataset, protocol documents, and analytic code will be made available immediately upon formal publication of the study results.

Access criteria: Data and code will be accessible via an open-access repository on the Open Science Framework (OSF) for researchers and clinicians interested in replication or meta-analysis.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07626060
Lead sponsor
Marmara University Pendik Training and Research Hospital
Responsible party
Emir Ünal (MD, Assistant Professor, Marmara University Pendik Training and Research Hospital) — Principal investigator
First posted
Jun 4, 2026
Start date
Jun 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jun 23, 2026

Study contacts

Emir Unal, Assistant Professor
Contact
emirunal@gmail.com
+905327766010
Emre Kudu, associate professor
Contact
dr.emre.kudu@gmail.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion